Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , , For transfection of a wide variety of cells, ... Features and benefits , , ... No transfection-complex removal needed for most cell lines , Transfection ... sensitive cell lines , High transfection efficiencies and minimal cytotoxicity, ...
... , , , , , ... QIAGEN GmbH, Hilden, Germany , , ... , of neuronal cells by delivery of either siRNA or ... Kosik reported silencing , of endogenous genes in primary rat ...
... , , , , For automated purification of genomic and mitochondrial , ... , Format: , 96-well ... QIAamp DNA Blood MDX Protocol, , ... frozen whole blood (with common anticoagulants , such as citrate and EDTA) , ...
Cached Biology Technology:Effectene Transfection Reagent 2Effectene Transfection Reagent 3Effectene Transfection Reagent 4Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 2Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 3Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 4Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 5Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 6QIAamp DNA Blood BioRobot MDx Kit 2
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
(Date:4/22/2014)... same crystal structure as a mineral first found in ... efficiency charts faster than almost anything researchers have seen ... way of using sunlight to generate electricity may be ... Department,s National Renewable Energy Laboratory (NREL) are analyzing the ... and broad spectrum of expertise to uncover the secrets ...
Breaking Biology News(10 mins):New electric fish genus and species discovered in Brazil's Rio Negro 2NREL unlocking secrets of new solar material 2NREL unlocking secrets of new solar material 3NREL unlocking secrets of new solar material 4NREL unlocking secrets of new solar material 5NREL unlocking secrets of new solar material 6
... BGI has added Applied Biosystems SOLiD System to BGI,s ... Systems have been installed and were thoroughly tested by ... high quality mate-pair data with read lengths up to ... far is 6.8 Gb mappable data per run with ...
... familiar with bar codes, those small black stripes with numbers below, ... on commercial products. We scan them at the grocery store or ... send them in for a rebate. Now imagine scanning a ... dinner to instantly verify the species, where it came from, its ...
... in Belgium have discovered that increasing age affects the way ... they become less likely to be diagnosed with aggressive tumours ... the cancer is increasingly likely to spread, particularly if the ... evidence on aging and lymph node involvement and this study ...
Cached Biology News:FISH-BOL: NOAA researchers help build a global reference library of DNA barcodes 2FISH-BOL: NOAA researchers help build a global reference library of DNA barcodes 3FISH-BOL: NOAA researchers help build a global reference library of DNA barcodes 4Breast cancers behave differently before and after the age of 70 2Breast cancers behave differently before and after the age of 70 3
Request Info...
...
Candida (IgG) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
Biology Products: